AstraZeneca announced it was acquiring Neogene Therapeutics, Inc. for $320 million.
This is the third M&A deal for the UK pharma giant this year.
The deal is the latest in a series of investments the company has made to strengthen its oncology pipeline.
Neogene's T-cell receptor (TCR-T) technologies are designed to deliver a fully individualized treatment approach.
This is accomplished by combining the patient's tumor biopsy with Neogene's proprietary T-cell receptor discovery platform.
TCR-Ts are a promising new therapeutic modality that targets genetic mutations that drive oncogenesis.
Combined with other novel approaches, such as immunotherapy, TCR-Ts are promising candidates for cancer treatment.
The company has built a strong pipeline of cancer drugs and has been aggressive against solid tumors.
Swipe Up and Subscribe to Our Push Notifications to Get Latest News on AstraZeneca